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AbstrAct
Objective
To characterise the clinical features of patients 
admitted to hospital with coronavirus disease 2019 
(covid-19) in the United Kingdom during the growth 
phase of the first wave of this outbreak who were 
enrolled in the International Severe Acute Respiratory 
and emerging Infections Consortium (ISARIC) World 
Health Organization (WHO) Clinical Characterisation 
Protocol UK (CCP-UK) study, and to explore risk factors 
associated with mortality in hospital.
Design
Prospective observational cohort study with rapid 
data gathering and near real time analysis.
setting
208 acute care hospitals in England, Wales, and 
Scotland between 6 February and 19 April 2020. A 
case report form developed by ISARIC and WHO was 
used to collect clinical data. A minimal follow-up time 
of two weeks (to 3 May 2020) allowed most patients 
to complete their hospital admission.
ParticiPants
20 133 hospital inpatients with covid-19.
Main OutcOMe Measures
Admission to critical care (high dependency unit or 
intensive care unit) and mortality in hospital.
results
The median age of patients admitted to hospital with 
covid-19, or with a diagnosis of covid-19 made in 
hospital, was 73 years (interquartile range 58-82, 
range 0-104). More men were admitted than women 
(men 60%, n=12 068; women 40%, n=8065). The 
median duration of symptoms before admission was 
4 days (interquartile range 1-8). The commonest 
comorbidities were chronic cardiac disease (31%, 
5469/17 702), uncomplicated diabetes (21%, 
3650/17 599), non-asthmatic chronic pulmonary 
disease (18%, 3128/17 634), and chronic kidney 
disease (16%, 2830/17 506); 23% (4161/18 525) 
had no reported major comorbidity. Overall, 41% 
(8199/20 133) of patients were discharged alive, 
26% (5165/20 133) died, and 34% (6769/20 133) 
continued to receive care at the reporting date. 
17% (3001/18 183) required admission to high 
dependency or intensive care units; of these, 28% 
(826/3001) were discharged alive, 32% (958/3001) 
died, and 41% (1217/3001) continued to receive care 
at the reporting date. Of those receiving mechanical 
ventilation, 17% (276/1658) were discharged 
alive, 37% (618/1658) died, and 46% (764/1658) 
remained in hospital. Increasing age, male sex, and 
comorbidities including chronic cardiac disease, non-
asthmatic chronic pulmonary disease, chronic kidney 
disease, liver disease and obesity were associated 
with higher mortality in hospital.
cOnclusiOns
ISARIC WHO CCP-UK is a large prospective cohort 
study of patients in hospital with covid-19. The study 
continues to enrol at the time of this report. In study 
participants, mortality was high, independent risk 
factors were increasing age, male sex, and chronic 
comorbidity, including obesity. This study has shown 
the importance of pandemic preparedness and the 
need to maintain readiness to launch research studies 
in response to outbreaks.
stuDy registratiOn
ISRCTN66726260.
Introduction
The outbreak of disease caused by the novel severe 
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) was declared a pandemic by the World Health 
Organization on 11 March 2020.1 The WHO situation 
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WhAt Is AlreAdy knoWn on thIs topIc
Observational studies in China have reported risk factors associated with severe 
covid-19 that requires hospital admission
Studies describing the features and outcomes of patients with severe covid-19 
who have been admitted to hospital in Europe are lacking
Older male adults, people with diabetes, hypertension, cardiovascular disease, 
or chronic respiratory disease are at greater risk of severe covid-19 that requires 
hospital admission and higher levels of care, and are at higher risk of death
WhAt thIs study Adds
This rapid prospective investigation of patients with covid-19 admitted to 
hospital in England, Wales, and Scotland showed that obesity, chronic kidney 
disease, and liver disease were also associated with increased hospital mortality
Obesity is a major additional risk factor that was not highlighted in data from 
China
Severe covid-19 leads to a prolonged hospital stay and a high mortality rate; 
over a quarter of inpatients in this study had died at the time of reporting, and 
nearly a third remained in hospital
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report dated 30 April 2020 stated 3 090 445 people 
had confirmed coronavirus disease 2019 (covid-19) 
and 217 769 people had died across the world.2
In the wake of the influenza A H1N1 pandemic 
(2009) and the emergence of Middle East respiratory 
syndrome coronavirus (2012), it was recognised that 
the effectiveness of a response to a future pandemic 
threat would critically depend on the speed and 
focus of that response. The United Kingdom set up 
and maintained a “sleeping” prepandemic suite of 
protocols, documents, and agreements in preparation 
for future outbreaks. The International Severe Acute 
Respiratory and emerging Infections Consortium 
(ISARIC) WHO Clinical Characterisation Protocol 
UK (CCP-UK) study was a core component of this 
portfolio.3 Further details about ISARIC WHO CCP-UK 
can be found at https://isaric4c.net and in the online 
supplement.
In response to the emergence of SARS-CoV-2 and its 
pandemic potential, the ISARIC WHO CCP-UK study 
was activated on 17 January 2020, in time to enrol 
the first wave of patients with covid-19 admitted to 
hospitals in England and Wales. The first confirmed 
patient with covid-19 in the UK was reported on 31 
January 2020.
Hospital admission rates for patients with covid-19 
have been difficult to estimate because rates depend 
on the prevalence of community testing and admission 
criteria, which vary between countries. However, 
an estimated one in 10 to one in five adults have 
illnesses of sufficient severity to warrant hospital 
admission.4 Patients have mostly been admitted with 
severe acute respiratory infection or severe acute 
respiratory syndrome according to the previous WHO 
case definitions.5 6 The provision of intensive care also 
varies between countries. Studies first from China, and 
more recently from Europe and the United States, have 
found rates of admission to intensive care range from 
5% to 32%.7 8 Old age, chronic major comorbidity, 
and male sex have consistently been associated with 
increased mortality.9-12
In this first report of the ISARIC WHO CCP-UK 
study, we characterise the clinical features of patients 
admitted to hospital with covid-19 in England, 
Scotland, and Wales during the growth phase of the 
first wave of this outbreak, up to 19 April 2020. Future 
reports will include Northern Ireland. We describe 
all patient outcomes as known on 3 May 2020 and 
explore risk factors associated with mortality in 
hospital. 
Methods
study design and setting
The ISARIC WHO CCP-UK (National Institute for Health 
Research Clinical Research Network Central Portfolio 
Management System ID: 14152) study is an ongoing 
prospective cohort study in 208 acute care hospitals 
in England, Scotland, and Wales. The protocol 
(supplementary material 2), revision history, case 
report form (version 9.2; supplementary material 3), 
information leaflets, consent forms and details of the 
Independent Data and Material Access Committee are 
available online.21
Participants
Inclusion criteria were people of all ages who were 
admitted to one of 208 acute care hospitals in England, 
Scotland, and Wales with proven or high likelihood of 
infection with a pathogen of public health interest, 
defined as SARS-CoV-2 for this event by Public Health 
England. Reverse transcriptase polymerase chain 
reaction was the only mode of testing available during 
the period of study. The decision to test was at the 
discretion of the clinician attending the patient, and 
not defined by protocol. The enrolment criterion “high 
likelihood of infection” reflects that a preparedness 
protocol cannot assume that a diagnostic test will 
be available for an emergent pathogen. Site training 
emphasises that only patients who tested positive for 
covid-19 were eligible for enrolment.
National guidance was provided by Public Health 
England and other UK public health agencies that 
advised who to test based on clinical case definitions 
for possible covid-19 (online supplement). We also 
included patients who had been admitted for a separate 
condition but had tested positive for covid-19 during 
their hospital stay. We collected additional biological 
samples for research purposes when consent was given 
(please see online supplement for details of consent 
procedures and biological samples). These samples are 
currently undergoing analysis and we will present the 
results when they become available. Patients were only 
enrolled during their index admission. We used three 
tiers in the ISARIC WHO CCP-UK protocol. Patients in 
tier 0 had clinical information from their routine health 
records uploaded into the case report form. Consent 
was not required for collection of depersonalised 
routine healthcare data for research in England and 
Wales. A waiver for consent was given by the Public 
Benefit and Privacy Panel in Scotland. Tier 1 and 2 of 
the protocol involve additional biological sampling for 
research purposes for which consent by, or assent for, 
participants was obtained.
Data collection
We collected baseline demographic data on a paper 
case report form (version 9.2; supplementary material 
2) that was developed by ISARIC and WHO for use in 
outbreak investigations. Data were uploaded from 
admission, and usually before hospital episodes 
were complete, to a REDCap database (Research 
Electronic Data Capture, Vanderbilt University, US, 
hosted by University of Oxford, UK). We aimed to 
record measures of illness severity and routine blood 
test results at a minimum of four time points: day of 
hospital admission (day 1), day 3, day 6, day 9, and day 
of any admission to critical care. We recorded relevant 
treatments that patients received in hospital, level of 
care (ward based, high dependency unit, or intensive 
care unit), complications, and details of discharge or 
death while in hospital. Further information about 
these variables can be found in the online supplement.
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Outcomes
The main outcomes were critical care admission (high 
dependency unit or intensive care unit) and mortality 
in hospital or palliative discharge. We chose a priori 
to restrict analysis of outcomes to patients who were 
admitted more than two weeks before data extraction 
(3 May 2020) to enable most patients to finish their 
hospital admission.
bias
Research nurses relied on local covid-19 test reports 
to enrol patients. Capacity to enrol was limited by staff 
resources at times of high covid-19 activity. Otherwise 
we are unable to comment on the potential selection 
bias of our cohort. We are in the process of linking to 
routine administrative healthcare data and will be able 
to make comparisons at that point.
Missing data
The nature of the study means that a large amount of 
data were missing, particularly during the later parts 
of the growth curve of the UK outbreak. Because this 
paper is mainly descriptive, we have not performed 
any imputation for missing data, and describe the data 
as they stand. To reduce the impact of missing data 
on outcome analyses, we restricted these analyses to 
patients who had been admitted for at least two weeks 
before data extraction.
statistical analyses
Continuous data are summarised as median 
(interquartile range) and categorical data as frequency 
(percentage). For univariate comparisons, the Mann-
Whitney U test or Kruskal-Wallis test were used. We 
compared categorical data by using the χ2 test.
We used several approaches to model survival. 
Discharge from hospital was considered an absorbing 
state, meaning that once discharged, patients were 
considered no longer at risk of death. Patients who 
were discharged were not censored and held within the 
risk set, therefore accounting for the competing risk of 
discharge on death. We checked this approach by using 
a formal Fine and Gray competing risks approach. 
Hierarchical Cox proportional hazards approaches 
included geographical region (clinical commissioning 
group or health board) as a random intercept. We 
used a parsimonious criterion based model building 
approach based on several principles: clinically 
relevant explanatory variables were identified a 
priori for exploration; population stratification was 
incorporated; interactions were checked at first 
order level; final model selection was informed by 
log likelihood tests and the concordance statistic, 
with appropriate assumptions checked including 
the distribution of residuals and requirement for 
proportional hazards. We set statistical significance 
at 5%. All tests were two sided. We analysed data by 
using R (R Core Team version 3.6.3, Vienna, Austria), 
with packages including tidyverse, finalfit, survival, 
cmprsk, and coxme.
Patient and public involvement
This was an urgent public health research study in 
response to a Public Health Emergency of International 
Concern. Patients or the public were not involved in 
the design, conduct, or reporting of this rapid response 
research.
results
On behalf of ISARIC WHO CCP-UK, 2468 research 
nurses, administrators, and medical students enrolled 
20 133 patients who were admitted with covid-19 
to 208 hospitals in England, Scotland, and Wales 
between 6 February and 14:00 on 19 April 2020 
(table 1 and fig E1). This figure represents 34% of the 
59 215 covid-19 admissions in these countries. The 
median time from onset of symptoms of covid-19 in 
the community to presentation at hospital was 4 days 
(interquartile range 1-8; n=16 221).
age and sex
The median age of patients was 73 years (interquartile 
range 58-82, range 0-104; fig 1); 310 patients (1.5%) 
were less than 18 years old and 194 (1.0%) were 
less than 5 years old. More men (59.9%, n=12 068) 
than women (40.1%, n=8065) were admitted to 
hospital with covid-19. One hundred women (10%) 
of reproductive age (n=1033) were recorded as being 
pregnant.
symptoms
The most common symptoms were cough (68.9%, 
12 896/18 730), fever (71.6%, 12 499/17 452), and 
shortness of breath (71.2%, 12 107/16 999; fig 2, top 
left panel), though these data reflect the case definition. 
Only 4.5% (855/19 178) of patients reported no 
symptoms on admission. We found a high degree of 
overlap between the three most common symptoms 
(fig 2, lower left panel).
Clusters of symptoms on admission were apparent 
(fig E2). The most common symptom cluster 
encompassed the respiratory system: cough, sputum, 
shortness of breath, and fever. We also observed three 
other clusters: one encompassing musculoskeletal 
symptoms (myalgia, joint pain, headache, and 
fatigue); a cluster of enteric symptoms (abdominal 
pain, vomiting, and diarrhoea); and less commonly, 
a mucocutaneous cluster. Twenty nine per cent 
(5384/18 605) of all patients complained of enteric 
symptoms on admission, mostly in association with 
respiratory symptoms; however, 4% of all patients 
described enteric symptoms alone.
comorbidities
Figure 2 (top right panel) and table 1 show major 
comorbidities recorded on admission. The most common 
major comorbidities were chronic cardiac disease 
(30.9%, 5469/17 702), diabetes without complications 
(20.7%, 3650/17 599), chronic pulmonary disease 
excluding asthma (17.7%, 3128/17 634), chronic 
kidney disease (16.2%, 2830/17 506), and asthma 
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characteristics Male Female all
Total No (%) 12 068 (59.9) 8065 (40.1) 20 133
Age at admission (n=20 133)
 Median (interquartile range) 72.0 (58.0-81.0) 74.0 (58.0-84.0) 72.9 (58.0-82.0)
Age (n=20 133)
 <18 180 (1.5) 130 (1.6) 310 (1.5)
 18-39 534 (4.4) 533 (6.6) 1067 (5.3)
 40-50 888 (7.4) 530 (6.6) 1418 (7.0)
 50-59 1728 (14.3) 980 (12.2) 2708 (13.5)
 60-69 2115 (17.5) 1181 (14.6) 3296 (16.4)
 70-79 2972 (24.6) 1720 (21.3) 4692 (23.3)
 ≥80 3651 (30.3) 2991 (37.1) 6642 (33.0)
Any comorbidity (n=18 525)
 No 2591 (23.4) 1570 (21.1) 4161 (22.5)
 Yes 8492 (76.6) 5872 (78.9) 14 364 (77.5)
Chronic cardiac disease (n=17 702)
 No 7086 (66.8) 5147 (72.6) 12 233 (69.1)
 Yes 3527 (33.2) 1942 (27.4) 5469 (30.9)
Chronic pulmonary disease, not asthma (n=17 634)
 No 8616 (81.7) 5890 (83.1) 14 506 (82.3)
 Yes 1931 (18.3) 1197 (16.9) 3128 (17.7)
Asthma (n=17 535)
 No 9274 (88.6) 5721 (80.9) 14 995 (85.5)
 Yes 1192 (11.4) 1348 (19.1) 2540 (14.5)
Smoker (n=14 184)
 Never smoked 5030 (58.8) 3938 (69.9) 8968 (63.2)
 Former smoker 2972 (34.8) 1392 (24.7) 4364 (30.8)
 Yes 549 (6.4) 303 (5.4) 852 (6.0)
Chronic kidney disease (n=17 506)
 No 8792 (84.0) 5884 (83.5) 14 676 (83.8)
 Yes 1671 (16.0) 1159 (16.5) 2830 (16.2)
Diabetes without complications (n=17 599)
 No 8254 (78.3) 5695 (80.7) 13 949 (79.3)
 Yes 2290 (21.7) 1360 (19.3) 3650 (20.7)
Diabetes with complications (n=17 516)
 No 9628 (91.8) 6589 (93.8) 16 217 (92.6)
 Yes 860 (8.2) 439 (6.2) 1299 (7.4)
Obesity (n=16 081)
 No 8725 (90.6) 5671 (87.8) 14 396 (89.5)
 Yes 900 (9.4) 785 (12.2) 1685 (10.5)
Chronic neurological disorder (n=17 382)
 No 9222 (88.6) 6189 (88.7) 15 411 (88.7)
 Yes 1181 (11.4) 790 (11.3) 1971 (11.3)
Dementia (n=17 459)
 No 9211 (88.2) 5888 (83.9) 15 099 (86.5)
 Yes 1232 (11.8) 1128 (16.1) 2360 (13.5)
Malignancy (n=17 354)
 No 9251 (89.2) 6360 (91.0) 15 611 (90.0)
 Yes 1117 (10.8) 626 (9.0) 1743 (10.0)
Moderate or severe liver disease (n=17 360)
 No 10 181 (98.0) 6869 (98.5) 17 050 (98.2)
 Yes 204 (2.0) 106 (1.5) 310 (1.8)
Mild liver disease (n=17 331)
 No 10 195 (98.3) 6855 (98.5) 17 050 (98.4)
 Yes 174 (1.7) 107 (1.5) 281 (1.6)
Chronic haematological disease (n=17 328)
 No 9951 (96.0) 6684 (96.0) 16 635 (96.0)
 Yes 415 (4.0) 278 (4.0) 693 (4.0)
Rheumatological disorder (n=17 289)
 No 9562 (92.4) 6031 (86.9) 15 593 (90.2)
 Yes 787 (7.6) 909 (13.1) 1696 (9.8)
Malnutrition (n=16 695)
 No 9768 (97.8) 6531 (97.4) 16 299 (97.6)
 Yes 222 (2.2) 174 (2.6) 396 (2.4)
Previous immunosuppressant drug treatment (n=18 009)
 Yes 876 (8.1) 791 (11.0) 1667 (9.3)
 No 9339 (86.6) 6032 (83.5) 15 371 (85.4)
 Not applicable 573 (5.3) 398 (5.5) 971 (5.4)
table 1 | baseline characteristics of 20 133 patients with coronavirus disease 2019 stratified by sex. Data are numbers 
(percentages) unless stated otherwise
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(14.5%, 2540/17 535). Of 18 525 patients, 22.5% 
(4161) had no documented major comorbidity. There 
was little overlap between the three most common 
comorbidities (fig 2, lower right panel). 
Six per cent (852/14 184) of patients were current 
smokers, 30.8% (4364) were previous smokers, and 
63.2% (8968) had never smoked. Figure E3 shows the 
pattern of major comorbidity stratified by age.
level of care
A high proportion of patients required admission 
to high dependency or intensive care units (17%, 
Admission date
No of patients
Female patients
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Fig 1 | Patients with coronavirus disease 2019 (covid-19) stratified by age and sex (top panel), and date of hospital 
admission with covid-19 by sex (lower panel). Outcomes are discharge from hospital, ongoing care, and death at time 
of report (19 april 2020, n=20 133)
characteristics Male Female all
Previous anti-infective treatment (n=18 017)
 No 1940 (18.0) 1311 (18.2) 3251 (18.0)
 Yes 8285 (76.8) 5520 (76.4) 13 805 (76.6)
 Not applicable 569 (5.3) 392 (5.4) 961 (5.3)
AIDS/HIV (n=17 251)
 No 10 259 (99.5) 6909 (99.6) 17 168 (99.5)
 Yes 55 (0.5) 28 (0.4) 83 (0.5)
table 1 | continued
 o
n
 15 June 2020 at BVA. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m1985 on 22 May 2020. Downloaded from 
RESEARCH
6 doi: 10.1136/bmj.m1985 | BMJ 2020;369:m1985 | the bmj
3001/18 183; fig 3), and 55% (9244/16 849) received 
high flow oxygen at some point during their admission. 
Sixteen per cent of patients (2670/16 805) were 
treated with non-invasive ventilation, while 10% 
(1658/16 866) received invasive ventilation.
Patient outcomes
Overall, 41% (8199/20 133) of patients were dis-
charged alive, 26% (5165/20 133) died, and 34% 
(6769/20 133) continued to receive care at the date of 
reporting (fig 4). The median age of patients who died 
ComorbiditySymptoms
Proportion of patients with comorbidities (%)Proportion of patients with symptoms (%)
Cough
Fever
Shortness of breath
Fatigue
Confusion
Cough (sputum)
Diarrhoea
Nausa/vomiting
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Cough (blood)
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Ear pain
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Chronic cardiac disease
Diabetes without complications
Chronic pulmonary disease
Chronic kidney disease
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Chronic neurological disorder
Malignancy
Rheumatological disorder
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Fig 2 | Presenting symptoms and comorbidities in patients in hospital with coronavirus disease 2019 (covid-19). top left panel: symptoms by 
frequency of presentation (see table e1 for values); lower left panel: scaled euler diagram of overlap of commonest symptoms; top right panel: 
comorbidities by frequency (see table 1 for values); lower right panel: scaled euler diagram of overlap of commonest comorbidities
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in hospital from covid-19 in the study was 80 years, 
and only 11% (559/4880) of these patients had no 
documented major comorbidity.
For patients who received only ward care, 
47% (7203/15 297) were discharged alive, 26% 
(3954/15 297) died, and 27% (4140/15 297) remained 
in hospital at the date of reporting. As expected, 
outcomes were worse for those who needed higher 
levels of care.
Of patients admitted to critical care (high depen-
dency unit or intensive care unit), 28% (826/3001) 
were discharged alive, 32% (958/3001) died, and 
41% (1217/3001) continued to receive care at the 
date of reporting. Although the patients who received 
mechanical ventilation were younger than the overall 
cohort (61 years, interquartile range 52-69), only 17% 
(276/1658) had been discharged alive by 19 April 
2020, 37% (618/1658) had died, and 46% (764/1658) 
continued to receive care.
Length of stay increased with age for patients 
discharged alive (fig E4). For patients who died, we 
found no association between age and time to death, 
with around 80% dying before day 14 of hospital 
admission.
association of pre-existing patient characteristics 
and survival
The online supplement (table E4) describes univariable 
and multivariable associations with mortality. Figure 
5 shows variables that remained significant in the 
multivariable model. Increasing age was a strong 
predictor of mortality in hospital after adjusting for 
major comorbidity (reference age <50 years): 50-59 
years, hazard ratio 2.63 (95% confidence interval 2.06 
to 3.35, P<0.001); 60-69 years, 4.99 (3.99 to 6.25, 
P<0.001); 70-79 years, 8.51 (6.85 to 10.57, P<0.001); 
≥80 years, 11.09 (8.93 to 13.77, P<0.001). Female 
sex was associated with lower mortality (0.81, 0.75 
to 0.86, P<0.001). Chronic cardiac disease, chronic 
non-asthmatic pulmonary disease, chronic kidney 
disease, obesity, chronic neurological disorder (such 
as stroke), dementia, malignancy, and liver disease 
were also associated with increased hospital mortality. 
An interactive infographic is available at https://
isaric4c.net/info. This information must not be used 
as a predictive tool in practice or to inform individual 
treatment decisions.
discussion
Principal findings
Patients with covid-19 usually presented with fever, 
cough, and shortness of breath, and met the WHO 
case definitions for severe acute respiratory infection 
or severe acute respiratory syndrome. The most 
common previous major comorbidities were chronic 
cardiac disease, diabetes, and chronic non-asthmatic 
pulmonary disease. Seventeen per cent of patients 
were admitted to critical care (high dependency unit 
or intensive care unit). Mortality in hospital was at 
least 26%, with 34% of the cohort still in hospital 
at the time of analysis; these proportions increased 
with escalating level of care. Factors associated 
with mortality in hospital were increasing age, male 
sex, and major comorbidities (cardiac disease, non-
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asthmatic pulmonary disease, kidney disease, liver 
disease, malignancy, obesity, and dementia).
The data presented in this study describe patients 
admitted to hospital during the growth phase of the 
SARS-CoV-2 pandemic in the UK. The first 101 patients 
were enrolled in the early phase of the outbreak as part 
of a high consequence infectious disease containment 
strategy that ended on 10 March 2020. These patients 
and others who were identified through screening in 
hospital, or who contracted covid-19 after admission 
(hospital acquired infection), are included in the 
855 patients who were admitted without covid-19 
symptoms. The impact these patients have had on 
the overall cohort characteristics has diminished as 
numbers have increased, and we believe it is important 
to keep these patients in the study. Other patients in 
our cohort without covid-19 symptoms are those who 
were diagnosed with the disease at the discretion of the 
clinician looking after them while staying in hospital 
for other reasons.
The pattern of disease we describe broadly reflects 
the pattern reported globally.7 Patients in our study 
had a higher median age and higher rates of chronic 
obstructive pulmonary disease and asthma than 
patients in China8 and the US.11 12 The prevalence of 
obesity in our study (11%) was considerably lower than 
the overall UK prevalence (29%).13 This proportion 
could reflect the relatively elderly male population 
admitted to hospital and misclassification or under 
reporting by admitting physicians. Our patients 
presented with a relatively short time interval between 
onset of symptoms and admission to hospital, which 
might also be a function of the older and vulnerable 
patient population.
The current case definition of cough and fever, if 
strictly applied, would miss 7% of our inpatients. 
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A smaller proportion, 4% of patients, presented 
with enteric symptoms only. This figure could be an 
underestimate because these patients fall outside 
standard criteria for testing. This enteric presentation 
risks misclassification of patients, and assignment 
to non-covid-19 care areas, which could pose a 
nosocomial transmission risk. Severe SARS-CoV-2 
infections are rare in people younger than 18 years, 
comprising only 1.5% of those admitted to hospital. 
Only 1.0% of those in our study were younger than 5 
years. The J shaped age distribution is starkly different 
to the U shaped age distribution seen in seasonal 
influenza and the W shaped distribution observed in 
the 2009 influenza pandemic.14 The reason why SARS-
CoV-19 has mostly spared children is not clear, but we 
speculate this could be because angiotensin converting 
enzyme 2 receptors are expressed differently in 
younger lungs.
Other studies have not widely reported that 
obesity as recognised by clinical staff is associated 
with mortality in hospital after adjustment for other 
comorbidities, age, and sex. Obesity was recognised as 
a risk factor in the 2009 influenza A H1N1 pandemic, 
but not for the 2012 Middle East respiratory syndrome 
coronavirus.15 16
The proportion of pregnant women in our cohort 
was small (10%), similar to the estimated proportion 
of pregnant women in the community.15 Pregnancy 
was not associated with mortality, in apparent contrast 
to influenza.17
comparison with other studies
The proportion of patients admitted to critical care 
in our study was similar to that reported in Italy 
(17%),18  19 and New York (14.2%),11 12 but higher 
than China.8 At the time of enrolment, the Intensive 
Care Society had issued guidance to its members that 
there would be no rationing of critical care admission 
until all capacity in the country had been exhausted. 
As far as we are aware, critical care capacity was not 
exceeded in the UK during the period of the study. We 
do not believe that any equipment shortages existed 
during this period that might have prompted more 
aggressive futility discussions.
Mortality in our cohort was high in patients admitted 
to general wards who were not admitted to critical care, 
which suggests that advanced care planning occurred. 
We were unable to capture treatment limiting decisions 
about level of care. The high median age of patients 
who died in the cohort (80 years) could partly explain 
the high mortality rate. Mortality rates were extremely 
high for patients who received invasive mechanical 
ventilation in the intensive care unit compared with the 
2009 influenza A H1N1 pandemic, for which mortality 
in intensive care was 31%.15 Our data were in line 
with the initial ICNARC (intensive care national audit 
and research centre) audit reports, which represent 
intensive care units in England, Wales, Scotland, and 
Northern Ireland.20
Outcome analyses only included patients who 
were admitted before 19 April to allow most patients 
to complete their hospital admission. However, an 
inherent reporting bias exists because the sickest 
of patients, particularly those admitted to intensive 
care, have the longest hospital stays; mortality rates 
in hospital could therefore increase. These mortality 
rates were considerably higher than the 24% mortality 
rate in hospital seen in patients in intensive care units 
in Italy19 and the US.11 12 The lower rate in the US 
could in part be explained by differences in healthcare 
systems and the proportion of intensive care unit beds 
to hospital beds between the two countries. In Italy, 
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Fig 5 | Multivariable cox proportional hazards model (age, sex, and major comorbidities), where hazard is death. 
Patients who were discharged were kept in the risk set (n=15 194; no of events=3911)
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a lower proportion of patients received mechanical 
ventilation, and most of their patients (72%) remained 
in hospital at the time of the analysis.19
The finding of independent associations of ad-
vancing age, male sex, chronic respiratory (non-
asthmatic) disease, chronic cardiac disease, and 
chronic neurological disease with mortality in hospital 
is in line with early international reports.9 10 However, 
although age adjusted mortality rates are high in 
elderly patients, most of these patients were admitted 
to hospital with symptoms of covid-19 and would not 
have been in hospital otherwise. Enhanced severity in 
male patients was seen across all ages.
strengths and limitations of study
ISARIC WHO CCP-UK stood ready to conduct large 
scale studies of pandemic outbreaks for eight years, 
enabling us to enrol 34% of all patients with covid-19 
admitted to 208 acute care hospitals across England, 
Wales and Scotland in the early phase of the pandemic.
Our study has some limitations. We do not currently 
have data on the inpatients that were not enrolled, or 
people managed in community settings, such as usual 
domestic residences and older people’s care homes. 
We are unable to comment on community risk factors 
that drive hospital admission except by inference from 
expected representation at admission. We will be 
linking to routine administrative healthcare datasets 
which will enable us to assess the presence of any 
selection bias.
A large amount of data were missing and we 
suggest there are two main reasons for this. Firstly, 
enrolment occurred in the nonlinear growth phase 
of the outbreak, and outcomes for recent admissions 
have not been reported yet; these admissions account 
for 18% of the total number of patients enrolled. 
Secondly, the research network was dealing with 
unprecedented numbers of patients at a time when 
many were seconded to clinical practice or themselves 
off sick. This study is ongoing, and further data are 
being added to case report forms.
We suggest it is possible that the sickest patients 
were enrolled in our study, and this could partly 
explain our high mortality rates in hospital. Some 
of the sickest patients in the study had the longest 
lengths of hospital stay and we do not have outcome 
data for all of these patients yet.
conclusions and policy implications
This large and rapidly conducted study of patients 
admitted to hospital in England, Wales, and Scotland 
with covid-19 shows the importance of putting plans in 
place for the study of epidemic and pandemic threats, 
and the need to maintain these plans. Our study 
identifies sectors of the population that are at greatest 
risk of a poor outcome, and reports the use of healthcare 
resources. Most patients with covid-19 experience mild 
disease. However, in our cohort, of those who were 
admitted to hospital two weeks before data extraction, 
less than half have been discharged alive and a quarter 
have died. The remainder continued to receive care at 
the date of reporting. Seventeen percent of patients 
admitted to hospital required critical care. Factors 
associated with mortality in hospital were increasing 
age, male sex, obesity, and major comorbidities.
ISARIC Coronavirus Clinical Characterisation Con-
sortium21 investigators have submitted regular reports 
to the UK Government’s New and Emerging Respiratory 
Virus Threats Advisory Group (NERVTAG)22 and the 
Scientific Advisory Group for Emergencies (SAGE).23 
Patient level data have been shared and independently 
analysed by the Scientific Pandemic Influenza Group 
on Modelling (SPI-M)24 and other investigators. 
Aggregated data have been shared with WHO in the 
ISARIC covid-19 report.
Studies such as this cannot be developed, approved, 
and opened from the start of a pandemic in time to 
inform case management and public health policy. Our 
study has shown the importance of forward planning 
and investment in preparedness studies. Over the next 
few months we will issue reports in The BMJ on specific 
topics and analyses that are key to understanding the 
impact of covid-19 and focus on improving patient 
outcomes.
autHOr aFFiliatiOns
1Centre for Medical Informatics, Usher Institute, University of 
Edinburgh, Edinburgh, UK
2Intensive Care Unit, Royal Infirmary Edinburgh, Edinburgh, UK
3Institute of Microbiology and Infection, University of Birmingham, 
Birmingham, UK
4National Institute of Health Research (NIHR) Health Protection 
Research Unit in Emerging and Zoonotic Infections, Liverpool, UK
5Institute of Infection and Global Health, Faculty of Health and Life 
Sciences, University of Liverpool, Liverpool, UK
6Institute of Translational Medicine, Faculty of Health and Life 
Sciences, University of Liverpool, Liverpool, UK
7Centre for Health Informatics, Computing and Statistics, Lancaster 
Medical School, Lancaster University, Bailrigg, UK
8ISARIC Global Support Centre, Centre for Tropical Medicine and 
Global Health, Nuffield Department of Medicine, University of 
Oxford, Oxford, UK
9Infectious Diseases Data Observatory, Centre for Tropical Medicine 
and Global Health, University of Oxford, Oxford, UK
10Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, 
UK
11Centre for Tropical Medicine and International Health, Nuffield 
Department of Medicine, University of Oxford, Oxford, UK
12Division of Epidemiology and Public Health, University of 
Nottingham School of Medicine, Nottingham, UK
13Medical Research Council University of Glasgow Centre for Virus 
Research, Glasgow, UK
14Queen’s Medical Research Institute, University of Edinburgh, 
Edinburgh, UK
15National Infection Service, Public Health England, London, UK
16Faculty of Medicine, Imperial College London, London, UK
17National Heart and Lung Institute, Faculty of Medicine, Imperial 
College London, London, UK
18Roslin Institute, University of Edinburgh, Edinburgh, UK
19NIHR Health Protection Research Unit in Emerging and Zoonotic 
Infections and Institute of Translational Medicine, Faculty of Health 
and Life Sciences, University of Liverpool, Liverpool, UK
20Respiratory Medicine, Alder Hey Children’s Hospital, Institute in 
The Park, University of Liverpool, Alder Hey Children’s Hospital, 
Liverpool L12 2AP, UK
The study protocol is available at http://isaric4c.net/protocols; study 
registry https://www.isrctn.com/ISRCTN66726260. This work uses 
data provided by patients and collected by the NHS as part of their 
 o
n
 15 June 2020 at BVA. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m1985 on 22 May 2020. Downloaded from 
RESEARCH
the bmj | BMJ 2020;369:m1985 | doi: 10.1136/bmj.m1985 11
care and support #DataSavesLives. We are extremely grateful to the 
2648 frontline NHS clinical and research staff and volunteer medical 
students who collected these data in challenging circumstances; and 
the generosity of the patients and their families for their individual 
contributions in these difficult times. We also acknowledge the 
support of Jeremy J Farrar, Nahoko Shindo, Devika Dixit, Nipunie 
Rajapakse, Piero Olliaro, Lyndsey Castle, Martha Buckley, Debbie 
Malden, Katherine Newell, Kwame O’Neill, Emmanuelle Denis, Claire 
Petersen, Scott Mullaney, Sue MacFarlane, Chris Jones, Nicole Maziere, 
Katie Bullock, Emily Cass, William Reynolds, Milton Ashworth, Ben 
Catterall, Louise Cooper, Terry Foster, Paul Matthew Ridley, Anthony 
Evans, Catherine Hartley, Chris Dunn, D Sales, Diane Latawiec, Erwan 
Trochu, Eve Wilcock, Innocent Gerald Asiimwe, Isabel Garcia-Dorival, 
J Eunice Zhang, Jack Pilgrim, Jane A Armstrong, Jordan J Clark, Jordan 
Thomas, Katharine King, Katie Neville, Alexandra Ahmed, Krishanthi 
S Subramaniam, Lauren Lett, Laurence McEvoy, Libby van Tonder, 
Lucia Alicia Livoti, Nahida S Miah, Rebecca K Shears, Rebecca Louise 
Jensen, Rebekah Penrice-Randal, Robyn Kiy, Samantha Leanne Barlow, 
Shadia Khandaker, Soeren Metelmann, Tessa Prince, Trevor R Jones, 
Benjamin Brennan, Agnieska Szemiel, Siddharth Bakshi, Daniella 
Lefteri, Maria Mancini, Julien Martinez, Angela Elliott, Joyce Mitchell, 
John McLauchlan, Aislynn Taggart, Oslem Dincarslan, Annette Lake, 
Claire Petersen, Scott Mullaney, and Graham Cooke.
ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C): 
Consortium lead investigator: J Kenneth Baillie; chief investigator: 
Malcolm G Semple; co-lead investigator: Peter JM Openshaw; ISARIC 
clinical coordinator: Gail Carson; co-investigators: Beatrice Alex, 
Benjamin Bach, Wendy S Barclay, Debby Bogaert, Meera Chand, 
Graham S Cooke, Annemarie B Docherty, Jake Dunning, Ana da 
Silva Filipe, Tom Fletcher, Christopher A Green, Julian A Hiscox, 
Antonia Ying Wai Ho, Peter W Horby, Samreen Ijaz, Saye Khoo, Paul 
Klenerman, Andrew Law, Wei Shen Lim, Alexander J Mentzer, Laura 
Merson, Alison M Meynert, Mahdad Noursadeghi, Shona C Moore, 
Massimo Palmarini, William A Paxton, Georgios Pollakis, Nicholas 
Price, Andrew Rambaut, David L Robertson, Clark D Russell, Vanessa 
Sancho-Shimizu, Janet T Scott, Tom Solomon, Shiranee Sriskandan, 
David Stuart, Charlotte Summers, Richard S Tedder, Emma C Thomson, 
Ryan S Thwaites, Lance CW Turtle, Maria Zambon; project managers: 
Hayley E Hardwick, Chloe Donohue, Jane Ewins, Wilna Oosthuyzen, 
Fiona Griffiths; data analysts: Lisa Norman, Riinu Pius, Tom M Drake, 
Cameron J Fairfield, Stephen Knight, Kenneth A Mclean, Derek Murphy, 
Catherine A Shaw; data and information system managers: Jo Dalton, 
Michelle Girvan, Egle Saviciute, Stephanie Roberts, Janet Harrison, 
Laura Marsh, Marie Connor; data integration and presentation: 
Gary Leeming, Andrew Law, Ross Hendry; material management: 
William Greenhalf, Victoria Shaw, Sarah McDonald; local principal 
investigators: Kayode Adeniji, Daniel Agranoff, Ken Agwuh, Dhiraj Ail, 
Ana Alegria, Brian Angus, Abdul Ashish, Dougal Atkinson, Shahedal 
Bari, Gavin Barlow, Stella Barnass, Nicholas Barrett, Christopher 
Bassford, David Baxter, Michael Beadsworth, Jolanta Bernatoniene, 
John Berridge, Nicola Best, Pieter Bothma, David Brealey, Robin 
Brittain-Long, Naomi Bulteel, Tom Burden, Andrew Burtenshaw, Vikki 
Caruth, David Chadwick, Duncan Chambler, Nigel Chee, Jenny Child, 
Srikanth Chukkambotla, Tom Clark, Paul Collini, Graham Cooke, 
Catherine Cosgrove, Jason Cupitt, Maria-Teresa Cutino-Moguel, Paul 
Dark, Chris Dawson, Samir Dervisevic, Phil Donnison, Sam Douthwaite, 
Ingrid DuRand, Ahilanadan Dushianthan, Tristan Dyer, Cariad Evans, 
Chi Eziefula, Chrisopher Fegan, Adam Finn, Duncan Fullerton, Sanjeev 
Garg, Sanjeev Garg, Atul Garg, Effrossyni Gkrania-Klotsas, Jo Godden, 
Arthur Goldsmith, Clive Graham, Elaine Hardy, Stuart Hartshorn, Daniel 
Harvey, Peter Havalda, Daniel B Hawcutt, Antonia Ho, Maria Hobrok, 
Luke Hodgson, Anita Holme, Anil Hormis, Michael Jacobs, Susan 
Jain, Paul Jennings, Agilan Kaliappan, Vidya Kasipandian, Stephen 
Kegg, Michael Kelsey, Jason Kendall, Caroline Kerrison, Ian Kerslake, 
Oliver Koch, Gouri Koduri, George Koshy, Shondipon Laha, Susan 
Larkin, Tamas Leiner, Patrick Lillie, James Limb, Vanessa Linnett, Jeff 
Little, Michael MacMahon, Emily MacNaughton, Ravish Mankregod, 
Huw Masson, Elijah Matovu, Katherine McCullough, Ruth McEwen, 
Manjula Meda, Gary Mills, Jane Minton, Mariyam Mirfenderesky, Kavya 
Mohandas, James Moon, Elinoor Moore, Patrick Morgan, Craig Morris, 
Katherine Mortimore, Samuel Moses, Mbiye Mpenge, Rohinton Mulla, 
Michael Murphy, Megan Nagel, Thapas Nagarajan, Mark Nelson, Igor 
Otahal, Mark Pais, Selva Panchatsharam, Hassan Paraiso, Brij Patel, 
Justin Pepperell, Mark Peters, Mandeep Phull, Stefania Pintus, Jagtur 
Singh Pooni, Frank Post, David Price, Rachel Prout, Nikolas Rae, Henrik 
Reschreiter, Tim Reynolds, Neil Richardson, Mark Roberts, Devender 
Roberts, Alistair Rose, Guy Rousseau, Brendan Ryan, Taranprit Saluja, 
Aarti Shah, Prad Shanmuga, Anil Sharma, Anna Shawcross, Jeremy 
Sizer, Richard Smith, Catherine Snelson, Nick Spittle, Nikki Staines, 
Tom Stambach, Richard Stewart, Pradeep Subudhi, Tamas Szakmany, 
Kate Tatham, Jo Thomas, Chris Thompson, Robert Thompson, Ascanio 
Tridente, Darell Tupper-Carey, Mary Twagira, Andrew Ustianowski, Nick 
Vallotton, Lisa Vincent-Smith, Shico Visuvanathan, Alan Vuylsteke, 
Sam Waddy, Rachel Wake, Andrew Walden, Tony Whitehouse, Paul 
Whittaker, Ashley Whittington, Meme Wijesinghe, Martin Williams, 
Lawrence Wilson, Sarah Wilson, Stephen Winchester, Martin Wiselka, 
Adam Wolverson, Daniel G Wooton, Andrew Workman, Bryan Yates, 
Peter Young.
Contributors: Conceptualisation: JKB, JD, GC, LM, JSN-V-T, PJMO, MGS. 
Formal analysis: ABD, FD, CG, EMH, PWH, LN, PJMO, RP, JMR, MGS. 
Writing original draft: ABD, PJMO, MGS. Writing reviewing and editing: 
JKB, ABD, JD, CG, CAG, EMH, PWH, JSN-V-T, PJMO, MGS, LS. Project 
administration: SH, HEH, CG, AH, KAH, JL, LM, DP, CDR. Investigation: 
EMH, PWH, CG, CAG, AH, MGS. Supervision: JKB, HEH, EMH, CG, AH, 
PWH, PJMO, MGS. Data curation: LM, SH, CJ. Validation: KAH, SH, CJ. 
Funding acquisition: JKB, GC, PWH, PJMO, MGS. MGS is guarantor and 
corresponding author for this work, and attests that all listed authors 
meet authorship criteria and that no others meeting the criteria have 
been omitted.
Funding: This work is supported by grants from: the National Institute 
for Health Research (NIHR; award CO-CIN-01), the Medical Research 
Council (MRC; grant MC_PC_19059), the NIHR Health Protection 
Research Unit in Emerging and Zoonotic Infections at University 
of Liverpool in partnership with Public Health England (PHE), in 
collaboration with Liverpool School of Tropical Medicine and the 
University of Oxford (NIHR award 200907), Wellcome Trust and 
Department for International Development (DID; 215091/Z/18/Z), 
and the Bill and Melinda Gates Foundation (OPP1209135), and 
Liverpool Experimental Cancer Medicine Centre for providing 
infrastructure support for this research (grant reference C18616/
A25153). JSN-V-T is seconded to the Department of Health and Social 
Care, England (DHSC). The views expressed are those of the authors 
and not necessarily those of the DHSC, DID, NIHR, MRC, Wellcome 
Trust, or PHE.
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: 
support from the National Institute for Health Research (NIHR), 
the Medical Research Council (MRC), the NIHR Health Protection 
Research Unit (HPRU) in Emerging and Zoonotic Infections at 
University of Liverpool, and Public Health England (PHE), Wellcome 
Trust, Department for International Development (DID), the Bill and 
Melinda Gates Foundation, Liverpool Experimental Cancer Medicine 
Centre, and Department of Health and Social Care (DHSC) for the 
submitted work; ABD reports grants from DHSC during the conduct 
of the study; grants from Wellcome Trust outside the submitted 
work; CAG reports grants from DHSC NIHR UK during the conduct 
of the study; FD is due to start a position at F Hoffmann-La Roche 
on 4 May 2020; PWH reports grants from Wellcome Trust, DID, Bill 
and Melinda Gates Foundation, and NIHR during the conduct of 
the study; JSN-V-T reports grants from DHSC during the conduct of 
the study, and is seconded to DHSC; PJMO reports personal fees 
from consultancies and from the European Respiratory Society; 
grants from MRC, MRC Global Challenge Research Fund, EU, NIHR 
Biomedical Research Centre, MRC/GSK, Wellcome Trust, NIHR (HPRU 
in Respiratory Infection), and is an NIHR senior investigator outside 
the submitted work; his role as President of the British Society for 
Immunology was unpaid but travel and accommodation at some 
meetings was provided by the Society; JKB reports grants from 
MRC UK; MGS reports grants from DHSC NIHR UK, MRC UK, HPRU in 
Emerging and Zoonotic Infections, University of Liverpool during the 
conduct of the study; other from Integrum Scientific LLC, Greensboro, 
NC, US outside the submitted work; the remaining authors declare 
no competing interests; no financial relationships with any 
organisations that might have an interest in the submitted work in 
the previous three years; and no other relationships or activities that 
could appear to have influenced the submitted work.
Ethical approval: Ethical approval was given by the South Central - 
Oxford C Research Ethics Committee in England (Ref 13/SC/0149), 
the Scotland A Research Ethics Committee (Ref 20/SS/0028), and the 
WHO Ethics Review Committee (RPC571 and RPC572, 25 April 2013).
Data sharing: We welcome applications for data and material access 
through our Independent Data and Material Access Committee 
(https://isaric4c.net).
The lead author (the manuscript’s guarantor) affirms that the 
manuscript is an honest, accurate, and transparent account of the 
study being reported; that no important aspects of the study have 
been omitted; and that any discrepancies from the study as planned 
(and, if relevant, registered) have been explained.
 o
n
 15 June 2020 at BVA. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m1985 on 22 May 2020. Downloaded from 
RESEARCH
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
Dissemination to participants and related patient and public 
communities: ISARIC4C has a public facing website and twitter 
account @CCPUKstudy. We are engaging with print and internet press, 
television, radio, news, and documentary programme makers. We 
will explore distribution of findings with The Asthma UK and British 
Lung Foundation Partnership, and take advice from NIHR Involve and 
GenerationR Alliance Young People’s Advisory Groups.
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